Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
293
archived clinical trials in
Benign Prostate Hyperplasia

A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Veterans Affairs Medical Center, Washington D.C.
mi
from
Washington D.C.,
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center, Washington D.C.
mi
from
Washington D.C.,
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Fayetteville, AK
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fayetteville, AK
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Memorial Hospital of Rhode Island
mi
from
Pawtucket, RI
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Memorial Hospital of Rhode Island
mi
from
Pawtucket, RI
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Hartford, CT
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Hartford, CT
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Idaho Falls, ID
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Idaho Falls, ID
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
University of Vermont College of Medicine
mi
from
Burlington, VT
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
University of Vermont College of Medicine
mi
from
Burlington, VT
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Medical University of South Carolina
mi
from
Charleston, SC
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
mi
from
Charleston, SC
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Topeka, KA
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Topeka, KA
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Alexandria, LA
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Alexandria, LA
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Bethesda, MD
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bethesda, MD
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Lansing, MI
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Lansing, MI
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Missoula, MT
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Missoula, MT
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Brooklyn, NY
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Brooklyn, NY
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Cincinnati, OH
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Cincinnati, OH
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Muskogee, OK
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Muskogee, OK
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
New York Methodist Hospital
mi
from
Brooklyn, NY
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
New York Methodist Hospital
mi
from
Brooklyn, NY
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Chattanooga, TN
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chattanooga, TN
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Fort Worth, TX
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Worth, TX
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
mi
from
Seattle, WA
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Seattle, WA
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Clinical Research Facility
mi
from
Alexandria, LA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Alexandria, LA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Worth, TX
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
Clinical Research Facility
mi
from
Brooklyn, NY
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Brooklyn, NY
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
New York Methodist Hospital
mi
from
Brooklyn, NY
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
New York Methodist Hospital
mi
from
Brooklyn, NY
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Chesapeake Urology
mi
from
Baltimore, MD
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Chesapeake Urology
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Urology Associates of Denver
mi
from
Englewood, CO
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Urology Associates of Denver
mi
from
Englewood, CO
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Sheldon J. Freedman, M.D., Ltd.
mi
from
Las Vegas, NV
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Sheldon J. Freedman, M.D., Ltd.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Scott and White Healthcare
mi
from
Temple, TX
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Scott and White Healthcare
mi
from
Temple, TX
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Genesis Research
mi
from
San Diego, CA
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Genesis Research
mi
from
San Diego, CA
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Shahram S. Gholami MD - A Professional Corp.
mi
from
San Jose, CA
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Shahram S. Gholami MD - A Professional Corp.
mi
from
San Jose, CA
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Advanced Urology Institute
mi
from
Daytona Beach, FL
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Advanced Urology Institute
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Pinellas Urology Inc
mi
from
Saint Petersburg, FL
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Pinellas Urology Inc
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Jean Brown Research
mi
from
Salt Lake City, UT
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Jean Brown Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Figtree Private Hospital
mi
from
Figtree,
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Figtree Private Hospital
mi
from
Figtree,
Click here to add this to my saved trials
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated:  12/31/1969
Chesapeake Urology
mi
from
Baltimore, MD
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated: 12/31/1969
Chesapeake Urology
mi
from
Baltimore, MD
Click here to add this to my saved trials
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated:  12/31/1969
Sheldon J. Freedman, M.D., Ltd.
mi
from
Las Vegas, NV
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated: 12/31/1969
Sheldon J. Freedman, M.D., Ltd.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated:  12/31/1969
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated: 12/31/1969
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials